Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (18551)
All Articles published online
|
Publishing Process of This Article
|
Feb 26, 2017 (publication date) through Apr 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91 [PMID: 28289523 DOI: 10.4330/wjc.v9.i2.76] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v9/i2/76.htm |
| Number | Citing Articles |
| 1 |
Vesna Vucic, Romana Masnikosa. Reference Module in Food Science. 2017; doi: 10.1016/B978-0-08-100596-5.21339-5
|
| 2 |
Ching-Hui Sia, Oliver Simon, Poay-Huan Loh, Kian Keong Poh. Atherosclerotic cardiovascular disease landscape in Singapore. Frontiers in Cardiovascular Medicine 2024; 11 doi: 10.3389/fcvm.2024.1342698
|
| 3 |
Carmen Lammi, Nadia Mulinacci, Lorenzo Cecchi, Maria Bellumori, Carlotta Bollati, Martina Bartolomei, Carlo Franchini, Maria Lisa Clodoveo, Filomena Corbo, Anna Arnoldi. Virgin Olive Oil Extracts Reduce Oxidative Stress and Modulate Cholesterol Metabolism: Comparison between Oils Obtained with Traditional and Innovative Processes. Antioxidants 2020; 9(9): 798 doi: 10.3390/antiox9090798
|
| 4 |
Iveta Merćep, Dominik Strikić, Ana Marija Slišković, Željko Reiner. New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review. Pharmaceuticals 2022; 15(7): 839 doi: 10.3390/ph15070839
|
| 5 |
Rahayu Zulkapli, Suhaila Abd Muid, Seok Mui Wang, Hapizah Nawawi. PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells. International Journal of Molecular Sciences 2023; 24(6): 5098 doi: 10.3390/ijms24065098
|
| 6 |
Poobalan Naidoo, Rashem Mothilal, Dirk Jacobus Blom. Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. JMIR Research Protocols 2018; 7(6): e163 doi: 10.2196/resprot.9248
|
| 7 |
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews 2020; 159: 34 doi: 10.1016/j.addr.2020.05.008
|
| 8 |
Rabia Shahid, Shaili S Naik, Shivana Ramphall, Swarnima Rijal, Vishakh Prakash, Heba Ekladios, Jiya Mulayamkuzhiyil Saju, Naishal Mandal, Nang I Kham, Pousette Hamid. Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review. Cureus 2022; doi: 10.7759/cureus.30942
|
| 9 |
Anindya Amanda Damayanti, Riana Rahmawati, Amany Taqiyyah Wardhani, Raisa Kamila Putri, Zavia Putri Salsabila. Proceedings of the 3rd International Conference on Cardiovascular Diseases (ICCvD 2021). 2023; : 293 doi: 10.2991/978-94-6463-048-0_33
|
| 10 |
Willemijn A. M. Schonck, Erik S. G. Stroes, G. Kees Hovingh, Laurens F. Reeskamp. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs 2024; 84(2): 165 doi: 10.1007/s40265-024-01995-9
|
| 11 |
Bhawneet Chadha, William H. Frishman. Review of the Protective Effects of Statins on Cognition. Cardiology in Review 2021; 29(6): 328 doi: 10.1097/CRD.0000000000000359
|
| 12 |
Satyavir Yadav, Jitendra Pal Singh Sawhney. Treatment of dyslipidemia in acute coronary syndrome. Indian Heart Journal 2024; 76: S51 doi: 10.1016/j.ihj.2024.01.011
|
| 13 |
Manasvi Gupta, Ramyashree Tummala, Raktim K. Ghosh, Colin Blumenthal, Karan Philip, Dhrubajyoti Bandyopadhyay, Hector Ventura, Prakash Deedwania. An update on pharmacotherapies in diabetic dyslipidemia. Progress in Cardiovascular Diseases 2019; 62(4): 334 doi: 10.1016/j.pcad.2019.07.006
|
| 14 |
Ivo P. van de Peppel, Anna Bertolini, Theo H. van Dijk, Albert K. Groen, Johan W. Jonker, Henkjan J. Verkade. Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice. Journal of Lipid Research 2019; 60(9): 1562 doi: 10.1194/jlr.M094607
|
| 15 |
Yoon kyung Chang, Tae-Jin Song. Management of Dyslipidemia after Stroke. Journal of the Korean Neurological Association 2022; 40(3): 217 doi: 10.17340/jkna.2022.3.1
|
| 16 |
Aditi Sharma, Chakshu Sharma, Lalit Sharma, Pranay Wal, Preeti Mishra, Nitin Sachdeva, Shivam Yadav, Celia Vargas De-La Cruz, Sandeep Arora, Vetriselvan Subramaniyan, Ravi Rawat, Tapan Behl, Mukesh Nandave. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis. Canadian Journal of Physiology and Pharmacology 2024; doi: 10.1139/cjpp-2023-0259
|
| 17 |
Shuo Geng, Yajun Wu, Liwu Li. Immune Homeostasis. Methods in Molecular Biology 2024; 2782: 25 doi: 10.1007/978-1-0716-3754-8_2
|
| 18 |
Maureen Sampson, Anna Wolska, Justine Cole, Rafael Zubirán, James D. Otvos, Jeff W. Meeusen, Leslie J. Donato, Allan S. Jaffe, Alan T. Remaley. Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations. Biomedicines 2022; 10(12): 3156 doi: 10.3390/biomedicines10123156
|
| 19 |
Giovanni Ciccarelli, Saverio D’Elia, Michele De Paulis, Paolo Golino, Giovanni Cimmino. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases 2018; 6(1): 22 doi: 10.3390/diseases6010022
|
| 20 |
Rajeev Chawla, SV Madhu, BM Makkar, Sujoy Ghosh, Banshi Saboo, Sanjay Kalra. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism 2020; 24(1): 1 doi: 10.4103/ijem.IJEM_225_20
|
| 21 |
Anastasia V. Poznyak, Dwaipayan Bharadwaj, Gauri Prasad, Andrey V. Grechko, Margarita A. Sazonova, Alexander N. Orekhov. Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. International Journal of Molecular Sciences 2021; 22(13): 7061 doi: 10.3390/ijms22137061
|
| 22 |
Roshni S. Patel, Emily M. Scopelliti, Oludamilola Olugbile. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. Annals of Pharmacotherapy 2018; 52(10): 1000 doi: 10.1177/1060028018771670
|
| 23 |
Yanqiang Zou, Zhang Chen, Xi Zhang, Jizhang Yu, Heng Xu, Jikai Cui, Yuan Li, Yuqing Niu, Cheng Zhou, Jiahong Xia, Jie Wu. Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.894789
|
| 24 |
Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A. Batais, Turky H. Almigbal, Ali Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A. ElToukhy, Naji Kholaif, Abdulhalim J. Kinsara, Manal Al-Kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Hani Altaradi, Khalid F Alhabib. The Gulf Achievement of Cholesterol Targets in Out-Patients Study
(GULF ACTION): Design, Rationale, and Preliminary Results. Current Vascular Pharmacology 2023; 21(4): 285 doi: 10.2174/1570161121666230710145604
|
| 25 |
Jitendra Gupta, Reena Gupta. PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders:
Heralding a New Therapeutic Era and Their Future Perspectives. Current Molecular Pharmacology 2023; 16(8) doi: 10.2174/1874467216666221202144813
|
| 26 |
Guhan R Venkataraman, Manuel A Rivas. Rare and common variant discovery in complex disease: the IBD case study. Human Molecular Genetics 2019; 28(R2): R162 doi: 10.1093/hmg/ddz189
|
| 27 |
Daniel Steffens, Peter Bramlage, Céline Scheeff, Mario Kasner, Adel Hassanein, Julian Friebel, Ursula Rauch-Kröhnert. PCSK9 inhibitors and cardiovascular outcomes. Expert Opinion on Biological Therapy 2020; 20(1): 35 doi: 10.1080/14712598.2020.1677604
|
| 28 |
Enrique Gallego-Colon, Aner Daum, Chaim Yosefy. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. European Journal of Pharmacology 2020; 878: 173114 doi: 10.1016/j.ejphar.2020.173114
|
| 29 |
Meghan L. Good, Parisa Malekzadeh, Samantha M. Ruff, Shreya Gupta, Amy Copeland, Karel Pacak, Naris Nilubol, Electron Kebebew, Dhaval Patel. Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. World Journal of Surgery 2020; 44(2): 552 doi: 10.1007/s00268-019-05175-9
|
| 30 |
Sarah J. Beecroft, Phillipa J. Lamont, Samantha Edwards, Hayley Goullée, Mark R. Davis, Nigel G. Laing, Gianina Ravenscroft. The Impact of Next-Generation Sequencing on the Diagnosis, Treatment, and Prevention of Hereditary Neuromuscular Disorders. Molecular Diagnosis & Therapy 2020; 24(6): 641 doi: 10.1007/s40291-020-00495-2
|
| 31 |
Harry Aldworth, Nigel M. Hooper. Post-translational regulation of the low-density lipoprotein receptor provides new targets for cholesterol regulation. Biochemical Society Transactions 2024; 52(1): 431 doi: 10.1042/BST20230918
|
| 32 |
Kitty Pham, Anwar Mulugeta, Amanda Lumsden, Elina Hyppӧnen. Genetically instrumented LDL‐cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome‐wide association study in the UK Biobank. British Journal of Clinical Pharmacology 2023; 89(10): 2992 doi: 10.1111/bcp.15793
|
| 33 |
扬 刘. Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis. Advances in Clinical Medicine 2023; 13(08): 12430 doi: 10.12677/ACM.2023.1381742
|
| 34 |
Barak Zafrir, Aya Egbaria, Nili Stein, Avishay Elis, Walid Saliba. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. Journal of Clinical Lipidology 2021; 15(1): 202 doi: 10.1016/j.jacl.2020.11.004
|
| 35 |
Yousuf Zafar, Yasar Sattar, Waqas Ullah, Sohaib Roomi, Mamoon-Ur- Rashid, Muhammad Shayan Khan, Laura Schmidt. Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis. Journal of Community Hospital Internal Medicine Perspectives 2020; 10(1): 32 doi: 10.1080/20009666.2019.1710952
|
| 36 |
Gopal Chandra Ghosh, Dhrubajyoti Bandyopadhyay, Raktim K. Ghosh, Samhati Mondal, Eyal Herzog. Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. The American Journal of Cardiology 2018; 122(7): 1272 doi: 10.1016/j.amjcard.2018.06.023
|
| 37 |
Annemarie Wolf, Hanna Sarah Kutsche, Rolf Schreckenberg, Martin Weber, Ling Li, Susanne Rohrbach, Rainer Schulz, Klaus-Dieter Schlüter. Autocrine effects of PCSK9 on cardiomyocytes. Basic Research in Cardiology 2020; 115(6) doi: 10.1007/s00395-020-00824-w
|
| 38 |
Lakshmi Lavanya Reddy, Swarup A. V. Shah, Chandrashekhar K. Ponde, Jamshed J. Dalal, Raj G. Jatale, Reeta J. Dalal, Rajesh M. Rajani, Sudhir K. Pillai, Chander V. Vanjani, Tester F. Ashavaid. Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India. Journal of Human Genetics 2021; 66(10): 983 doi: 10.1038/s10038-021-00924-y
|
| 39 |
Busarin Arunsak, Wasana Pratchayasakul, Patchareeya Amput, Kenneth Chattipakorn, Theetouch Tosukhowong, Sasiwan Kerdphoo, Thidarat Jaiwongkum, Chanisa Thonusin, Siripong Palee, Nipon Chattipakorn, Siriporn C Chattipakorn. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats. Archives of Biochemistry and Biophysics 2020; 689: 108470 doi: 10.1016/j.abb.2020.108470
|
| 40 |
Isis Paez, Yalena Prado, Pía Loren, Carmen G. Ubilla, Nelia Rodríguez, Luis A. Salazar. Cholesterol-Related lncRNAs as Response Predictors of Atorvastatin Treatment in Chilean Hypercholesterolemic Patients: A Pilot Study. Biomedicines 2023; 11(3): 742 doi: 10.3390/biomedicines11030742
|
| 41 |
Jay Shendure, Gregory M. Findlay, Matthew W. Snyder. Genomic Medicine–Progress, Pitfalls, and Promise. Cell 2019; 177(1): 45 doi: 10.1016/j.cell.2019.02.003
|
| 42 |
Natalie C. Ward, Michael M. Page, Gerald F. Watts. PCSK9 inhibition 2018: riding a new wave of coronary prevention. Clinical Science 2019; 133(2): 205 doi: 10.1042/CS20171300
|
| 43 |
Katrine Bjune, Lene Wierød, Soheil Naderi. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-34237-6
|
| 44 |
Allison B. Reiss, Neal Shah, Dalia Muhieddine, Juan Zhen, Jennifer Yudkevich, Lora J. Kasselman, Joshua DeLeon. PCSK9 in cholesterol metabolism: from bench to bedside. Clinical Science 2018; 132(11): 1135 doi: 10.1042/CS20180190
|
| 45 |
Emma M. O’Connell, Falk W. Lohoff. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. Frontiers in Neuroscience 2020; 14 doi: 10.3389/fnins.2020.00609
|
| 46 |
Adi prasad Bodapati, Ayesha Hanif, Donatus K Okafor, Gitika Katyal, Gursharan Kaur, Hafsa Ashraf, Safeera Khan. PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis. Cureus 2023; doi: 10.7759/cureus.46605
|
| 47 |
Roberto Cemin, Simona Casablanca, Davide Ermacora, Massimo Daves. The Importance of Being Aware of Intrinsic Methods’ Limitation in Low-Density Lipoprotein Cholesterol Determination to Correctly Identify Cardiovascular Risk: Is Direct Determination Obtained with the Roche System Systematically Overestimating LDL in Very High-Risk Patients with Triglycerides Concentration of Less than (<2.25 mmol/L)?. Journal of Clinical Medicine 2023; 12(13): 4422 doi: 10.3390/jcm12134422
|
| 48 |
BinBin Zheng-Lin, Alberto Ortiz. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018; 78(2): 215 doi: 10.1007/s40265-017-0858-2
|
| 49 |
Anna Gluba-Brzózka, Beata Franczyk, Magdalena Rysz-Górzyńska, Janusz Ławiński, Jacek Rysz. Emerging Anti-Atherosclerotic Therapies. International Journal of Molecular Sciences 2021; 22(22): 12109 doi: 10.3390/ijms222212109
|
| 50 |
Vishnu Priya Pulipati, Michael H. Davidson. Recent advances and emerging therapies in management of dyslipidemias. Trends in Cardiovascular Medicine 2021; 31(7): 419 doi: 10.1016/j.tcm.2020.08.007
|
| 51 |
Charles A. German, Michael D. Shapiro. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs 2020; 34(1): 1 doi: 10.1007/s40259-019-00399-6
|
| 52 |
Constantine E Kosmas, Andreas Skavdis, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta, Eliscer Guzman. <p>Safety and Tolerability of PCSK9 Inhibitors: Current Insights</p>. Clinical Pharmacology: Advances and Applications 2020; : 191 doi: 10.2147/CPAA.S288831
|
| 53 |
Manik Chhabra, Kota Vidyasagar, Sai Krishna Gudi, Jatin Sharma, Rishabh Sharma, Muhammed Rashid, Jie V. Zhao. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies. PLOS ONE 2022; 17(7): e0269531 doi: 10.1371/journal.pone.0269531
|
| 54 |
Dongqi Zhu, Hongyu Qin, Xiaojing Wang, Yuping Jia, Xuejian Wang, Lei Zhang. Discovery of [5,5′‐bibenzo[d][1,3]dioxol]‐6‐substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors. Chemical Biology & Drug Design 2023; 102(1): 153 doi: 10.1111/cbdd.14264
|
| 55 |
|
| 56 |
Ya-Nan Qiao, Yan-Li Zou, Shou-Dong Guo. Low-density lipoprotein particles in atherosclerosis. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.931931
|
| 57 |
Shengtao Xu, Shanshan Luo, Zheying Zhu, Jinyi Xu. Small molecules as inhibitors of PCSK9: Current status and future challenges. European Journal of Medicinal Chemistry 2019; 162: 212 doi: 10.1016/j.ejmech.2018.11.011
|
| 58 |
Daniela T. Fuller, Andrew T. Grainger, Ani Manichaikul, Weibin Shi. Genetic linkage of oxidative stress with cardiometabolic traits in an intercross derived from hyperlipidemic mouse strains. Atherosclerosis 2020; 293: 1 doi: 10.1016/j.atherosclerosis.2019.11.034
|
| 59 |
Martina Bartolomei, Carlotta Bollati, Jianqiang Li, Anna Arnoldi, Carmen Lammi. Assessment of the Cholesterol-Lowering Effect of MOMAST®: Biochemical and Cellular Studies. Nutrients 2022; 14(3): 493 doi: 10.3390/nu14030493
|
| 60 |
Maureen Sampson, Clarence Ling, Qian Sun, Roa Harb, Mohmed Ashmaig, Russell Warnick, Amar Sethi, James K. Fleming, James D. Otvos, Jeff W. Meeusen, Sarah R. Delaney, Allan S. Jaffe, Robert Shamburek, Marcelo Amar, Alan T. Remaley. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiology 2020; 5(5): 540 doi: 10.1001/jamacardio.2020.0013
|
| 61 |
Rida Zainab, Afshan Kaleem, Michał B. Ponczek, Roheena Abdullah, Mehwish Iqtedar, Daniel C. Hoessli, Emilio Gallicchio. Finding inhibitors for PCSK9 using computational methods. PLOS ONE 2021; 16(8): e0255523 doi: 10.1371/journal.pone.0255523
|
| 62 |
Natalie C. Ward, Gerald F. Watts. PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. Journal of Clinical Lipidology 2018; 12(4): 844 doi: 10.1016/j.jacl.2018.05.015
|
| 63 |
Zohaib Iqbal, Shaishav Dhage, Jamal Basheer Mohamad, Alaa Abdel-Razik, Rachelle Donn, Rayaz Malik, Jan Hoong Ho, Yifen Liu, Safwaan Adam, Basil Isa, Claudia Stefanutti, Handrean Soran. Efficacy and safety of PCSK9 monoclonal antibodies. Expert Opinion on Drug Safety 2019; 18(12): 1191 doi: 10.1080/14740338.2019.1681395
|
| 64 |
Stephen Daniels, Sonia Caprio, Umesh Chaudhari, Garen Manvelian, Marie T. Baccara-Dinet, Aurelie Brunet, Michel Scemama, Virginie Loizeau, Eric Bruckert. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. Journal of Clinical Lipidology 2020; 14(3): 322 doi: 10.1016/j.jacl.2020.03.001
|
| 65 |
Małgorzata Bednarska-Makaruk, Agnieszka Ługowska. Cholesterol. 2022; : 553 doi: 10.1016/B978-0-323-85857-1.00024-9
|
| 66 |
M. I. Voevoda, V. S. Gurevich, M. V. Ezhov, I. V. Sergienko. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia 2022; 62(6): 57 doi: 10.18087/cardio.2022.6.n2115
|
| 67 |
Wei Yin, Mark Rogge. Targeting RNA: A Transformative Therapeutic Strategy. Clinical and Translational Science 2019; 12(2): 98 doi: 10.1111/cts.12624
|
| 68 |
Smruti M Besekar, Sangita D Jogdand, Waqar M Naqvi. A Systematic Review of the Randomized Controlled Trials of Gemcabene and Its Therapeutic Uses. Cureus 2023; doi: 10.7759/cureus.36811
|
| 69 |
Leigh Goedeke, Alberto Canfrán-Duque, Noemi Rotllan, Balkrishna Chaube, Bonne M. Thompson, Richard G. Lee, Gary W. Cline, Jeffrey G. McDonald, Gerald I. Shulman, Miguel A. Lasunción, Yajaira Suárez, Carlos Fernández-Hernando. MMAB promotes negative feedback control of cholesterol homeostasis. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-26787-7
|
| 70 |
Gabriela Alexandra Solano Peña, Gabriela Fernanda Acurio Armas, Gabriela Alejandra Díaz Teran, Susana Patricia Palacios Serrano, Andrea Carolina Cobo Reyes, Daniel Albino Pullas Taboada, Gissel Katherine Carvajal Chango. Inhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa. Salud, Ciencia y Tecnología 2023; 3: 587 doi: 10.56294/saludcyt2023587
|
| 71 |
Yoonkyung Chang, Soojeong Eom, Minjeong Kim, Tae-Jin Song. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Medicina 2023; 59(4): 776 doi: 10.3390/medicina59040776
|
| 72 |
Nadir Ali, David M. Diamond, Sarah M. Rice. Ketogenic. 2023; : 205 doi: 10.1016/B978-0-12-821617-0.00016-4
|
| 73 |
Carmen Lammi, Maria Bellumori, Lorenzo Cecchi, Martina Bartolomei, Carlotta Bollati, Maria Lisa Clodoveo, Filomena Corbo, Anna Arnoldi, Nadia Mulinacci. Extra Virgin Olive Oil Phenol Extracts Exert Hypocholesterolemic Effects through the Modulation of the LDLR Pathway: In Vitro and Cellular Mechanism of Action Elucidation. Nutrients 2020; 12(6): 1723 doi: 10.3390/nu12061723
|
| 74 |
Chao Luan, Yingxue He, Wen Liu, Yicheng Rong, Jian Gao, Kang Xu, Hui Yu, Yu Hu, Jiaan Zhang, Kun Chen, Wenjie Guo. PCSK9 inhibition interrupts the cross-talk between keratinocytes and macrophages and prevents UVB-induced skin damage. Journal of Biological Chemistry 2023; 299(7): 104895 doi: 10.1016/j.jbc.2023.104895
|
| 75 |
Jiali Zhu, Xuemei Zhang, Xiu Chen, Yong Sun, Yaolan Dai, Chang Chen, Tiane Zhang, Zhiyong Yan. Studies on the regulation of lipid metabolism and the mechanism of the aqueous and ethanol extracts of Usnea. Biomedicine & Pharmacotherapy 2017; 94: 930 doi: 10.1016/j.biopha.2017.08.012
|
| 76 |
Nurjannatul Naim Kamaruddin, Nor Azwin Hajri, Yosie Andriani, Aina Farahiyah Abdul Manan, Tengku Sifzizul Tengku Muhammad, Habsah Mohamad. Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats. Molecules 2021; 26(16): 5094 doi: 10.3390/molecules26165094
|
| 77 |
Lin Jiang, Hui Jiang, Sheng Dai, Ying Chen, Youqiang Song, Clara Sze-Man Tang, Shirley Yin-Yu Pang, Shu-Leong Ho, Binbin Wang, Maria-Mercedes Garcia-Barcelo, Paul Kwong-Hang Tam, Stacey S Cherny, Mulin Jun Li, Pak Chung Sham, Miaoxin Li. Deviation from baseline mutation burden provides powerful and robust rare-variants association test for complex diseases. Nucleic Acids Research 2022; 50(6): e34 doi: 10.1093/nar/gkab1234
|
| 78 |
JinSook Yoon, DonO Kikkawa. Thyroid eye disease: From pathogenesis to targeted therapies. Taiwan Journal of Ophthalmology 2022; 12(1): 3 doi: 10.4103/tjo.tjo_51_21
|
| 79 |
Ricardo Fontes-Carvalho, Pedro Marques Silva, Elisabete Rodrigues, Francisco Araújo, Cristina Gavina, Jorge Ferreira, João Morais. Practical guide for the use of PCSK9 inhibitors in Portugal. Revista Portuguesa de Cardiologia (English Edition) 2019; 38(6): 391 doi: 10.1016/j.repce.2019.07.004
|
| 80 |
Oluwakemi Ebenezer, Pietro Comoglio, Gane Ka-Shu Wong, Jack A. Tuszynski. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. International Journal of Molecular Sciences 2023; 24(4): 4019 doi: 10.3390/ijms24044019
|
| 81 |
Shakir Ahamad, Shahnawaz A. Bhat. Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. Journal of Medicinal Chemistry 2022; 65(23): 15513 doi: 10.1021/acs.jmedchem.2c01290
|
| 82 |
Roberto CEMIN, Simona CASABLANCA, Davide ERMACORA, Massimo DAVES. Misurazione diretta del colesterolo-LDL e sue possibili conseguenze sulla terapia farmacologica. La Rivista Italiana della Medicina di Laboratorio 2024; 19(4) doi: 10.23736/S1825-859X.23.00217-7
|
| 83 |
Saverio Muscoli, Mihaela Ifrim, Massimo Russo, Francesco Candido, Angela Sanseviero, Marialucia Milite, Marco Di Luozzo, Massimo Marchei, Giuseppe Sangiorgi. Current Options and Future Perspectives in the Treatment of Dyslipidemia. Journal of Clinical Medicine 2022; 11(16): 4716 doi: 10.3390/jcm11164716
|
| 84 |
Marion Mussbacher, Manuel Salzmann, Barbara Haigl, José Basílio, Bernhard Hochreiter, Viola Gleitsmann, Bernhard Moser, Bastian Hoesel, Bianca E. Suur, Florian Puhm, Caroline Ungerböck, Mario Kuttke, Maria J. Forteza, Christoph J. Binder, Daniel F.J. Ketelhuth, Alice Assinger, Johannes A. Schmid. Ikk2-mediated inflammatory activation of arterial endothelial cells promotes the development and progression of atherosclerosis. Atherosclerosis 2020; 307: 21 doi: 10.1016/j.atherosclerosis.2020.06.005
|
| 85 |
Stella Talic, Clara Marquina Hernandez, Richard Ofori-Asenso, Danny Liew, Alice Owen, Marjana Petrova, Sean Lybrand, David Thomson, Jenni Ilomaki, Zanfina Ademi, Ella Zomer. Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. Current Problems in Cardiology 2022; 47(7): 100880 doi: 10.1016/j.cpcardiol.2021.100880
|
| 86 |
Andrew S. Bell, Josephin Wagner, Daniel B. Rosoff, Falk W. Lohoff. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. Neuroscience & Biobehavioral Reviews 2023; 149: 105155 doi: 10.1016/j.neubiorev.2023.105155
|
| 87 |
Usama Bin Ghaffar. Determinants of Risk Factors Associated with Aortic Atherosclerosis: A Quantitative Study in Forensic Autopsies. Biosciences Biotechnology Research Asia 2024; 21(1): 157 doi: 10.13005/bbra/3211
|
| 88 |
Matthew Perry Koppinger, Marissa Anne Lopez-Pier, Rinku Skaria, Preston Royal Harris, John P. Konhilas. Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow. American Journal of Physiology-Heart and Circulatory Physiology 2020; 319(1): H32 doi: 10.1152/ajpheart.00569.2019
|
| 89 |
Rupesh Maurya, Gargi Bhattacharjee, Nisarg Gohil, Khushal Khambhati, Shreya Shakhreliya, Aaradhya Bhatnagar, Priyanka Singh, Suresh Ramakrishna, Vijai Singh. Receptor Endocytosis and Signalling in Health and Disease - Part A. Progress in Molecular Biology and Translational Science 2023; 194: 333 doi: 10.1016/bs.pmbts.2022.09.010
|
| 90 |
Sylwester Rogula, Ewelina Błażejowska, Aleksandra Gąsecka, Łukasz Szarpak, Milosz J. Jaguszewski, Tomasz Mazurek, Krzysztof J. Filipiak. Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis. Journal of Clinical Medicine 2021; 10(11): 2467 doi: 10.3390/jcm10112467
|
| 91 |
Marion Laudette, Malin Lindbom, Muhammad Arif, Mathieu Cinato, Mario Ruiz, Stephen Doran, Azra Miljanovic, Mikael Rutberg, Linda Andersson, Martina Klevstig, Marcus Henricsson, Per-Olof Bergh, Entela Bollano, Nay Aung, J Gustav Smith, Marc Pilon, Tuulia Hyötyläinen, Matej Orešič, Rosie Perkins, Adil Mardinoglu, Malin C Levin, Jan Borén. Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovascular Research 2023; 119(7): 1537 doi: 10.1093/cvr/cvad041
|
| 92 |
Valentina Rodriguez, Jonathan D. Newman, Arthur Z. Schwartzbard. Towards more specific treatment for diabetic dyslipidemia. Current Opinion in Lipidology 2018; 29(4): 307 doi: 10.1097/MOL.0000000000000528
|
| 93 |
Alfonso Soler-Bistué, Angeles Zorreguieta, Marcelo E. Tolmasky. Bridged Nucleic Acids Reloaded. Molecules 2019; 24(12): 2297 doi: 10.3390/molecules24122297
|
| 94 |
Guangwei Huang, Xiyang Lu, Haiyan Zhou, Runhong Li, Qing Huang, Xinlin Xiong, Zhenhua Luo, Wei Li. PCSK9 inhibition protects against myocardial ischemia-reperfusion injury via suppressing autophagy. Microvascular Research 2022; 142: 104371 doi: 10.1016/j.mvr.2022.104371
|
| 95 |
Camille B. Carroll, Richard K.H. Wyse. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress. Journal of Parkinson's Disease 2017; 7(4): 545 doi: 10.3233/JPD-171203
|
| 96 |
Hideyuki Torikai, Mei-Hua Chen, Li Jin, Jiang He, John F. Angle, Weibin Shi. Atherogenesis in Apoe−/− and Ldlr−/− Mice with a Genetically Resistant Background. Cells 2023; 12(9): 1255 doi: 10.3390/cells12091255
|
| 97 |
Benjamin J. Tombling, Conan K. Wang, David J. Craik. EGF‐like and Other Disulfide‐rich Microdomains as Therapeutic Scaffolds. Angewandte Chemie International Edition 2020; 59(28): 11218 doi: 10.1002/anie.201913809
|
| 98 |
Mohammad Alkhalil. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. Current Drug Metabolism 2019; 20(1): 72 doi: 10.2174/1389200219666180816141827
|
| 99 |
Mohamed Toufic El Hussein, Aditi Sharma, Komal Parmar, Krupa Shelat. Pharmacotherapeutics for dyslipidemia management. The Nurse Practitioner 2023; 48(6): 36 doi: 10.1097/01.NPR.0000000000000059
|
| 100 |
Amino Acid Conjugates of 2-Mercaptobenzimidazole Ameliorates High-Fat Diet-Induced Hyperlipidemia in Rats via Attenuation of HMGCR, APOB, and PCSK9. ACS Omega 2022; 7(44): 40502 doi: 10.1021/acsomega.2c05735
|
| 101 |
Amit Rout, Ajaypaul Sukhi, Rahul Chaudhary, Kevin P Bliden, Udaya S Tantry, Paul A Gurbel. Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opinion on Investigational Drugs 2020; 29(1): 33 doi: 10.1080/13543784.2020.1708324
|
| 102 |
Esther Torres, Marian Goicoechea, Andrés Hernández, María L. Rodríguez Ferrero, Ana García, Nicolás Macías, Fernando Anaya. Efficacy of Evolocumab vs low‐density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). Journal of Clinical Apheresis 2020; 35(1): 9 doi: 10.1002/jca.21752
|
| 103 |
Victoria Harbour, Candice Casillas, Zain Siddiqui, Biplab Sarkar, Sreya Sanyal, Peter Nguyen, Ka Kyung Kim, Abhishek Roy, Patricia Iglesias-Montoro, Saloni Patel, Frank Podlaski, Peter Tolias, William Windsor, Vivek Kumar. Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides. ACS Applied Bio Materials 2020; 3(12): 8978 doi: 10.1021/acsabm.0c01229
|
| 104 |
Ramyashree Tummala, Manasvi Gupta, Arvind Reddy Devanabanda, Dhrubajyoti Bandyopadhyay, Wilbert S. Aronow, Kausik K. Ray, Mamas Mamas, Raktim K. Ghosh. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. Annals of Medicine 2022; 54(1): 1287 doi: 10.1080/07853890.2022.2059559
|
| 105 |
Donatella Zodda, Rosario Giammona, Silvia Schifilliti. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy 2018; 6(1): 10 doi: 10.3390/pharmacy6010010
|
| 106 |
Tingting Yuan, Yi Zhong, Yingge Wang, Ting Zhang, Rui Lu, Minya Zhou, Yaoyao Lu, Kunning Yan, Yajie Chen, Zhehui Hu, Jingyan Liang, Jianglin Fan, Yong Cheng. Generation of hyperlipidemic rabbit models using multiple sgRNAs targeted CRISPR/Cas9 gene editing system. Lipids in Health and Disease 2019; 18(1) doi: 10.1186/s12944-019-1013-8
|
| 107 |
Marios Papasotiriou, Theodoros Ntrinias, Eirini Savvidaki, Evangelos Papachristou, Dimitrios S. Goumenos. Treatment of Mixed Dyslipidemia With Alirocumab in a Kidney Transplant Recipient: A Case Report. Transplantation Proceedings 2021; 53(9): 2775 doi: 10.1016/j.transproceed.2021.08.027
|
| 108 |
Carrie Palmer. New Directions in Managing Dyslipidemia. The Journal for Nurse Practitioners 2019; 15(1): 73 doi: 10.1016/j.nurpra.2018.08.033
|
| 109 |
Rafael Campo. Estudios clínicos con inhibidores de la PCSK9. Revista Colombiana de Cardiología 2017; 24: 13 doi: 10.1016/j.rccar.2017.08.019
|
| 110 |
Amber Carelse, Helgard M Rossouw, Nicolene Steyn, Janine Martins, Tahir S Pillay. Calculated LDL-cholesterol: comparability of the extended Martin/Hopkins, Sampson/NIH, Friedewald and four other equations in South African patients. Journal of Clinical Pathology 2023; : jcp-2023-208916 doi: 10.1136/jcp-2023-208916
|
| 111 |
Carmen Lammi, Carlotta Bollati, Davide Lecca, Maria Pia Abbracchio, Anna Arnoldi. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9D374Y Pathway: in vitro Characterization of its Dual Hypocholesterolemic Behavior. Nutrients 2019; 11(7): 1665 doi: 10.3390/nu11071665
|
| 112 |
Daniel B. Rosoff, Andrew S. Bell, Jeesun Jung, Josephin Wagner, Lucas A. Mavromatis, Falk W. Lohoff. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function. Journal of the American College of Cardiology 2022; 80(7): 653 doi: 10.1016/j.jacc.2022.05.041
|
| 113 |
Nivas Shyamala, Kishore Kumar Gundapaneni, Rajesh Kumar Galimudi, Mohini Aiyengar Tupurani, Chiranjeevi Padala, Kaushik Puranam, Keerthi Kupsal, Ramanjaneyulu Kummari, Srilatha Reddy Gantala, Krishna Reddy Nallamala, Sanjib K. Sahu, Surekha Rani Hanumanth. PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients. The Journal of Gene Medicine 2021; 23(8) doi: 10.1002/jgm.3346
|
| 114 |
Zhu Luo, Zhijun Huang, Feng Sun, Fang Guo, Yingying Wang, Sheena Kao, Guoping Yang, Jie Huang, Jiaxin Li, Sylvia Zhao, YanLing He. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of Clinical Lipidology 2023; 17(3): 392 doi: 10.1016/j.jacl.2023.04.010
|
| 115 |
Omonzejie E. Imaralu, Chandrakala Aluganti Narasimhulu, Pawan K. Singal, Dinender K. Singla. Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications. Canadian Journal of Physiology and Pharmacology 2024; 102(01): 14 doi: 10.1139/cjpp-2023-0223
|
| 116 |
Elena Domingo, Patrice Marques, Vera Francisco, Laura Piqueras, Maria-Jesus Sanz. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?. Pharmacological Research 2024; 200: 107058 doi: 10.1016/j.phrs.2024.107058
|
| 117 |
Adrianna Dec, Aleksandra Niemiec, Eliza Wojciechowska, Mateusz Maligłówka, Łukasz Bułdak, Aleksandra Bołdys, Bogusław Okopień. Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy. International Journal of Molecular Sciences 2023; 24(7): 6858 doi: 10.3390/ijms24076858
|
| 118 |
Gurpreet Kaur Batra, Chakrant Mothsara, Swati Sharma, Aishwarya Anand, Alka Bhatia, Shobhit Bhansali, Sant Ram, Arnab Pal, Amol N. Patil. Dose–Response Evaluation of Scopoletin, a Phytochemical, in a High-Fructose High-Fat Diet-Induced Dyslipidemia Model in Wistar Rats. Journal of Medicinal Food 2023; 26(5): 319 doi: 10.1089/jmf.2022.K.0120
|
| 119 |
Candace L. Jackson, Yihong Deng, Xiaoxi Yao, Holly Van Houten, Nilay D. Shah, Stephen Kopecky. Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. Journal of Clinical Lipidology 2021; 15(2): 339 doi: 10.1016/j.jacl.2020.12.009
|
| 120 |
Sonia Singh, Manas Kumar Jha. Review on PCSK9: A Pertinent Therapeutic Target in Cardiovascular Disease. Current Bioactive Compounds 2024; 20(1) doi: 10.2174/0115734072270060230921093431
|
| 121 |
Olivia M. Kim, Tatyana K. Givens, Emily G. Tang, Jennifer J. Schimmer, Tanya Ramsey, Kayla Boyd, Thomas Delate. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use. Journal of Cardiovascular Pharmacology 2023; 81(5): 339 doi: 10.1097/FJC.0000000000001404
|
| 122 |
Gbolahan Olatunji, Emmanuel Kokori, Ismaila Ajayi Yusuf, Olumide Akinmoju, Emmanuel Egbunu, Ifeanyichukwu Muogbo, Kaleb Lema, Sai Gutham Kanagala, Samuel Owolabi, Muili Abdulbasit, Nicholas Aderinto. Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials. Current Problems in Cardiology 2024; 49(4): 102419 doi: 10.1016/j.cpcardiol.2024.102419
|
| 123 |
Chanisa Thonusin, Patcharapong Pantiya, Thidarat Jaiwongkam, Sasiwan Kerdphoo, Busarin Arunsak, Patchareeya Amput, Siripong Palee, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn. A proprotein convertase subtilisin/kexin type 9 inhibitor provides comparable efficacy with lower detriment than statins on mitochondria of oxidative muscle of obese estrogen-deprived rats. Menopause 2020; 27(10): 1155 doi: 10.1097/GME.0000000000001586
|
| 124 |
Ioannis D. Karantas, Mehmet E. Okur, Neslihan Ü. Okur, Panoraia I. Siafaka. Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21(5): 815 doi: 10.2174/1871530320666200810144004
|
| 125 |
Alisha Aman, Eric A. W. Slob, Joey Ward, Breda Cullen, Nicholas Graham, Donald M. Lyall, Naveed Sattar, Rona J. Strawbridge, Toni-Kim Clarke. Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization. PLOS ONE 2022; 17(12): e0279381 doi: 10.1371/journal.pone.0279381
|
| 126 |
Joyson J. Karakunnel, Nam Bui, Latha Palaniappan, Keith T. Schmidt, Kenneth W. Mahaffey, Briggs Morrison, William D. Figg, Shivaani Kummar. Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1710-5
|
| 127 |
Tao Cai, Nashmi Naife Al-Jubairi, Heitor O. Santos, Ivan G.O. de Souza, Youdong Chen. Does letrozole treatment have favorable effects on the lipid profile? A systematic review and meta-analysis of randomized clinical trials. Steroids 2021; 172: 108875 doi: 10.1016/j.steroids.2021.108875
|
| 128 |
V. V. Ryabov, Ya. V. Alekseeva, A. E. Gombozhapova, Ya. V. Sokolova, R. S. Karpov. Atherosclerosis. Macrophages. Viral infections. The Siberian Journal of Clinical and Experimental Medicine 2021; 36(2): 14 doi: 10.29001/2073-8552-2021-36-2-14-22
|
| 129 |
Rajeev Chawla, S. V. Madhu, B. M. Makkar, Sujoy Ghosh, Banshi Saboo, Sanjay Kalra. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries 2020; 40(S1): 1 doi: 10.1007/s13410-020-00819-2
|
| 130 |
Natalie C. Ward, Gerald F. Watts. Therapeutic Lipidology. Contemporary Cardiology 2021; : 615 doi: 10.1007/978-3-030-56514-5_33
|
| 131 |
AjayK Shukla, Rekha Mehani. Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. Journal of Family Medicine and Primary Care 2019; 8(7): 2249 doi: 10.4103/jfmpc.jfmpc_406_19
|
| 132 |
Angela Lee, Sunny Wei, Adel Schwertani. A Notch more: Molecular players in bicuspid aortic valve disease. Journal of Molecular and Cellular Cardiology 2019; 134: 62 doi: 10.1016/j.yjmcc.2019.05.018
|
| 133 |
George Valeriu Moldovan, Adina Huțanu, Liliana Demian, Laszlo Hadadi, Bogdan Mănescu, Minodora Dobreanu. The utility of MLPA in Familial Hypercholesterolemia diagnosis. Acta Marisiensis - Seria Medica 2021; 67(3): 162 doi: 10.2478/amma-2021-0021
|
| 134 |
Benjamin J. Tombling, Conan K. Wang, David J. Craik. EGF‐artige und andere disulfidreiche Mikrodomänen als therapeutische Molekülgerüste. Angewandte Chemie 2020; 132(28): 11314 doi: 10.1002/ange.201913809
|
| 135 |
Aida Collado, Elena Domingo, Laura Piqueras, Maria-Jesus Sanz. Primary hypercholesterolemia and development of cardiovascular disorders: Cellular and molecular mechanisms involved in low-grade systemic inflammation and endothelial dysfunction. The International Journal of Biochemistry & Cell Biology 2021; 139: 106066 doi: 10.1016/j.biocel.2021.106066
|
| 136 |
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy 2019; 20(16): 2007 doi: 10.1080/14656566.2019.1649394
|
| 137 |
Michele Scognamiglio, Dario Costa, Antonio Sorriento, Claudio Napoli. Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Current Pharmaceutical Design 2019; 25(1): 85 doi: 10.2174/1381612825666190130101108
|
| 138 |
Dean L. Kellogg, Susan Fisher-Hoch, Joseph B. McCormick, Anand Prasad. Searching for the Genetic Determinants of Peripheral Arterial Disease. Cardiology in Review 2019; 27(3): 145 doi: 10.1097/CRD.0000000000000231
|
| 139 |
Dieter K. Lam, Patricia R. Feliciano, Amena Arif, Tanggis Bohnuud, Thomas P. Fernandez, Jason M. Gehrke, Phil Grayson, Kin D. Lee, Manuel A. Ortega, Courtney Sawyer, Noah D. Schwaegerle, Leila Peraro, Lauren Young, Seung-Joo Lee, Giuseppe Ciaramella, Nicole M. Gaudelli. Improved cytosine base editors generated from TadA variants. Nature Biotechnology 2023; 41(5): 686 doi: 10.1038/s41587-022-01611-9
|
| 140 |
Ada Cuevas, Rodrigo Alonso. Bempedoic acid: A new player in lipid-lowering therapies. Journal of Clinical Lipidology 2020; 14(5): 615 doi: 10.1016/j.jacl.2020.08.014
|
| 141 |
Ricardo Fontes‐Carvalho, Pedro Marques Silva, Elisabete Rodrigues, Francisco Araújo, Cristina Gavina, Jorge Ferreira, João Morais. Guia prático para a utilização dos inibidores da PCSK9 em Portugal. Revista Portuguesa de Cardiologia 2019; 38(6): 391 doi: 10.1016/j.repc.2019.05.005
|
| 142 |
Bhavani Shankara Bagepally, Akhil Sasidharan. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. European Journal of Clinical Pharmacology 2022; 78(3): 351 doi: 10.1007/s00228-021-03242-6
|
| 143 |
PRIYANKA VENUNGOPAL, KARTHIKEYAN BALAKRISHNAN, DAMAL KANDADAI SRIRAM, MELVIN GEORGE. INCLISIRAN (LEQVIO): A FIRST-IN-CLASS SMALL INTERFERING RNA THERAPEUTIC DRUG APPROVED BY FDA FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR DYSLIPIDEMIA. Asian Journal of Pharmaceutical and Clinical Research 2022; : 42 doi: 10.22159/ajpcr.2022.v15i12.46054
|
| 144 |
Dominic Mitchell, Jason R. Guertin, Jacques LeLorier. Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. Molecular Diagnosis & Therapy 2018; 22(6): 641 doi: 10.1007/s40291-018-0356-6
|
| 145 |
X. Pintó, I. Sarasa. Nuevas perspectivas en el tratamiento de la hipercolesterolemia desde la disponibilidad de los inhibidores de la proteína PCSK9. Hipertensión y Riesgo Vascular 2019; 36(4): 213 doi: 10.1016/j.hipert.2019.05.005
|
| 146 |
Junying Miao, Xiaoling Zang, Xiaoling Cui, Jun Zhang. Autophagy: Biology and Diseases. Advances in Experimental Medicine and Biology 2020; 1207: 237 doi: 10.1007/978-981-15-4272-5_18
|
| 147 |
Hongju Liu, Huiyi Xie, Changqun Li, Lingling Wang, Qiling Chen, Xin Ouyang, Chong Yan. Diaporisoindole B Reduces Lipid Accumulation in THP-1 Macrophage Cells via MAPKs and PPARγ–LXRα Pathways and Promotes the Reverse Cholesterol Transport by Upregulating SR-B1 and LDLR in HepG2 Cells. Journal of Natural Products 2022; 85(12): 2769 doi: 10.1021/acs.jnatprod.2c00715
|
| 148 |
Roberto Garcia, Jaime Burkle. New and Future Parenteral Therapies for the Management of Lipid Disorders. Archives of Medical Research 2018; 49(8): 538 doi: 10.1016/j.arcmed.2019.01.001
|
| 149 |
Jianqiang Li, Carlotta Bollati, Martina Bartolomei, Angelica Mazzolari, Anna Arnoldi, Giulio Vistoli, Carmen Lammi. Hempseed (Cannabis sativa) Peptide H3 (IGFLIIWV) Exerts Cholesterol-Lowering Effects in Human Hepatic Cell Line. Nutrients 2022; 14(9): 1804 doi: 10.3390/nu14091804
|
| 150 |
Alexander D. Mazura, Claus U. Pietrzik. Endocrine Regulation of Microvascular Receptor—Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9—Mediated Regulation. Pharmaceutics 2023; 15(4): 1268 doi: 10.3390/pharmaceutics15041268
|
| 151 |
Chanisa Thonusin, Nattayaporn Apaijai, Thidarat Jaiwongkam, Sasiwan Kerdphoo, Busarin Arunsak, Patchareeya Amput, Siripong Palee, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn. The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats. Toxicology and Applied Pharmacology 2019; 382: 114741 doi: 10.1016/j.taap.2019.114741
|
| 152 |
Hong Lin, Juan I. Luengo. Exploiting binding-site arginines in drug design: Recent examples. Bioorganic & Medicinal Chemistry Letters 2020; 30(19): 127442 doi: 10.1016/j.bmcl.2020.127442
|
| 153 |
S. K. Zyryanov, O. I. Butranova. New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy. Russian Journal of Cardiology 2022; 27(11): 5271 doi: 10.15829/1560-4071-2022-5271
|
| 154 |
Veronika A. Myasoedova, Alessio L. Ravani, Beatrice Frigerio, Vincenza Valerio, Donato Moschetta, Paola Songia, Paolo Poggio. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacological Research 2018; 136: 74 doi: 10.1016/j.phrs.2018.08.020
|
| 155 |
Sanjana Jagannath, Nandini D. Chilkunda. High cholesterol-supplemented diet during gestation and lactation alters liver glycosaminoglycans and associated lipoprotein receptors and results in fat accumulation in adulthood. Nutrition Research 2021; 93: 50 doi: 10.1016/j.nutres.2021.07.002
|
| 156 |
Pilar Hoyos, Vittorio Pace, Andrés Alcántara. Biocatalyzed Synthesis of Statins: A Sustainable Strategy for the Preparation of Valuable Drugs. Catalysts 2019; 9(3): 260 doi: 10.3390/catal9030260
|
| 157 |
Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, Christie M Ballantyne, Salim S Virani. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vascular Health and Risk Management 2022; : 555 doi: 10.2147/VHRM.S275739
|
| 158 |
Grigoris Thermos, Konstantinos I. Tosios. Gingival Ischemia and Petechiae in a Patient Medicated With PCSK9 Inhibitor for Hypercholesterolemia: An Adverse Drug Event?. Clinical Advances in Periodontics 2019; 9(1): 20 doi: 10.1002/cap.10043
|
| 159 |
Hamideh Amirfakhryan. Vaccination against atherosclerosis: An overview. Hellenic Journal of Cardiology 2020; 61(2): 78 doi: 10.1016/j.hjc.2019.07.003
|
| 160 |
Semira Abdi Beshir, Nadia Hussain, Asim Ahmed Elnor, Amira S. A. Said. Umbrella Review on Non-Statin Lipid-Lowering Therapy. Journal of Cardiovascular Pharmacology and Therapeutics 2021; 26(5): 437 doi: 10.1177/10742484211002943
|
| 161 |
Isabella Giacomini, Federico Gianfanti, Maria Andrea Desbats, Genny Orso, Massimiliano Berretta, Tommaso Prayer-Galetti, Eugenio Ragazzi, Veronica Cocetta. Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.682911
|
| 162 |
Ji Liu, Jin Chang, Ying Jiang, Xiandi Meng, Tianmeng Sun, Lanqun Mao, Qiaobing Xu, Ming Wang. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. Advanced Materials 2019; 31(33) doi: 10.1002/adma.201902575
|
| 163 |
Roohollah Sattari, Abbasali Palizban, Hossein Khanahmad. Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection. Cardiovascular Drugs and Therapy 2020; 34(4): 475 doi: 10.1007/s10557-020-06986-y
|
| 164 |
Velimir Altabas, Lora Stanka Kirigin Biloš. The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair. International Journal of Molecular Sciences 2022; 23(5): 2663 doi: 10.3390/ijms23052663
|
| 165 |
Michael A. Hicks, Claire Y.C. Hou, Arya Iranmehr, Krisztina Marosi, Ewen Kirkness. Target discovery using biobanks and human genetics. Drug Discovery Today 2020; 25(2): 438 doi: 10.1016/j.drudis.2019.09.014
|
| 166 |
James Milner, Andreia Cunha, Carlota Gamboa-Cruz, Julie Reis, Márcia Campos, Natália António. Recent major advances in cardiovascular pharmacotherapy. European Journal of Clinical Pharmacology 2018; 74(7): 853 doi: 10.1007/s00228-018-2453-1
|
| 167 |
Pierre Giguère, Salin Nhean, Alice L. Tseng, Christine A. Hughes, Jonathan B. Angel. Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications. Canadian Journal of Cardiology 2019; 35(3): 326 doi: 10.1016/j.cjca.2018.12.020
|
| 168 |
Dongdong Wang, Yang Yang, Yingnan Lei, Nikolay T. Tzvetkov, Xingde Liu, Andy Wai Kan Yeung, Suowen Xu, Atanas G. Atanasov, Qiang Ma. Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products. Pharmacological Reviews 2019; 71(4): 596 doi: 10.1124/pr.118.017178
|
| 169 |
Alexander D. Mazura, Anke Ohler, Steffen E. Storck, Magdalena Kurtyka, Franka Scharfenberg, Sascha Weggen, Christoph Becker-Pauly, Claus U. Pietrzik. PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier. Cellular and Molecular Life Sciences 2022; 79(4) doi: 10.1007/s00018-022-04237-x
|
| 170 |
Yajnavalka Banerjee, Anca Pantea Stoian, Arrigo Francesco Giuseppe Cicero, Federica Fogacci, Dragana Nikolic, Alexandros Sachinidis, Ali A. Rizvi, Andrej Janez, Manfredi Rizzo. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opinion on Drug Safety 2022; 21(1): 9 doi: 10.1080/14740338.2022.1988568
|
| 171 |
Aisha Siddiq A, Asha Martin. Crocetin exerts hypocholesterolemic effect by inducing LDLR and inhibiting PCSK9 and Sortilin in HepG2 cells. Nutrition Research 2022; 98: 41 doi: 10.1016/j.nutres.2021.08.005
|
| 172 |
Marko Kumric, Hrvoje Urlic, Josko Bozic, Marino Vilovic, Tina Ticinovic Kurir, Duska Glavas, Dino Miric, Jaksa Zanchi, Anteo Bradaric-Slujo, Mislav Lozo, Josip A. Borovac. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside. International Journal of Molecular Sciences 2023; 24(9): 8062 doi: 10.3390/ijms24098062
|
| 173 |
Amy Elizabeth Morgan, Mark Tomás Mc Auley. Cholesterol Homeostasis: An In Silico Investigation into How Aging Disrupts Its Key Hepatic Regulatory Mechanisms. Biology 2020; 9(10): 314 doi: 10.3390/biology9100314
|
| 174 |
Arcangelo Iannuzzi, Paolo Rubba, Marco Gentile, Vania Mallardo, Ilenia Calcaterra, Alessandro Bresciani, Giuseppe Covetti, Gianluigi Cuomo, Pasquale Merone, Anna Di Lorenzo, Roberta Alfieri, Emilio Aliberti, Francesco Giallauria, Matteo Nicola Dario Di Minno, Gabriella Iannuzzo. Carotid Atherosclerosis, Ultrasound and Lipoproteins. Biomedicines 2021; 9(5): 521 doi: 10.3390/biomedicines9050521
|
| 175 |
Amy S. Etheridge, Paul J. Gallins, Dereje Jima, K. Alaine Broadaway, Mark J. Ratain, Erin Schuetz, Eric Schadt, Adrian Schroder, Cliona Molony, Yihui Zhou, Karen L. Mohlke, Fred A. Wright, Federico Innocenti. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex‐Biased Phenotypes. Clinical Pharmacology & Therapeutics 2020; 107(6): 1383 doi: 10.1002/cpt.1751
|
| 176 |
Maria Lorenzi, Baishali Ambegaonkar, Carl A. Baxter, Jeroen Jansen, Michael J. Zoratti, Glenn Davies. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical Research in Cardiology 2019; 108(5): 487 doi: 10.1007/s00392-018-1379-z
|
| 177 |
Swapnil Raj, Liston Augustine Dsouza, Shailendra Pratap Singh, Abhinav Kanwal. Sirt6 Deacetylase: A Potential Key Regulator in the Prevention of Obesity, Diabetes and Neurodegenerative Disease. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.598326
|
| 178 |
Taher A. Salaheldin, Kavitha Godugu, Dhruba J. Bharali, Kazutoshi Fujioka, Nabil Elshourbagy, Shaker A. Mousa. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia. Nanomedicine: Nanotechnology, Biology and Medicine 2022; 40: 102480 doi: 10.1016/j.nano.2021.102480
|
| 179 |
Brian Hon Yin Chung, Jeffrey Fong Ting Chau, Gane Ka-Shu Wong. Rare versus common diseases: a false dichotomy in precision medicine. npj Genomic Medicine 2021; 6(1) doi: 10.1038/s41525-021-00176-x
|
| 180 |
Thomas Duflot, Ly Tu, Matthieu Leuillier, Hind Messaoudi, Déborah Groussard, Guillaume Feugray, Saïda Azhar, Raphaël Thuillet, Fabrice Bauer, Marc Humbert, Vincent Richard, Christophe Guignabert, Jérémy Bellien. Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. Metabolites 2021; 11(11): 784 doi: 10.3390/metabo11110784
|
| 181 |
Zhixin Ma, Hongtao Liu, Shan Jiang, Wenya Li, Yue Li, Yiting Liu, Li Wang, Wenyan Li. Identification of benzothiazoles as novel PCSK9 inhibitors. Bioorganic & Medicinal Chemistry Letters 2024; 97: 129542 doi: 10.1016/j.bmcl.2023.129542
|
| 182 |
Alacia J Tarpley. New Frontier in Lipids: PCSK9 Inhibitors and Implications for the Life Insurance Industry. Journal of Insurance Medicine 2018; 47(4): 230 doi: 10.17849/insm-47-4-1-6.1
|
| 183 |
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis, Christos Mantzoros. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism 2017; 74: 43 doi: 10.1016/j.metabol.2017.04.007
|
| 184 |
Henry T. Greely. Human Germline Genome Editing: An Assessment. The CRISPR Journal 2019; 2(5): 253 doi: 10.1089/crispr.2019.0038
|
| 185 |
Truong Phuong Kim, Lao Thuan Duc, Huyen Le Thuy Ai. The Major Molecular Causes of Familial Hypercholesterolemia. Asian Journal of Pharmaceutical Research and Health Care 2018; 10(2): 60 doi: 10.18311/ajprhc/2018/20031
|
| 186 |
Penelope Poppy Janpen Sucharitkul, Keely Louise Jones, David Julian Ashbridge Scott, Marc Aaron Bailey. Lipid Optimization in Lower Extremity Peripheral Arterial Disease. Annals of Vascular Surgery 2021; 76: 542 doi: 10.1016/j.avsg.2021.03.055
|
| 187 |
Si Cheng, Zhe Xu, Shengzhe Bian, Xi Chen, Yanfeng Shi, Yanran Li, Yunyun Duan, Yang Liu, Jinxi Lin, Yong Jiang, Jing Jing, Zixiao Li, Yilong Wang, Xia Meng, Yaou Liu, Mingyan Fang, Xin Jin, Xun Xu, Jian Wang, Chaolong Wang, Hao Li, Siyang Liu, Yongjun Wang. The STROMICS genome study: deep whole-genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay. Cell Discovery 2023; 9(1) doi: 10.1038/s41421-023-00582-8
|